May 29, 2026 | Pfizer's $10.5B Innovent Deal Extends China Licensing Wave; BMS Mezigdomide Phase 3  episode artwork

EPISODE · May 30, 2026 · 8 MIN

May 29, 2026 | Pfizer's $10.5B Innovent Deal Extends China Licensing Wave; BMS Mezigdomide Phase 3

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

Pfizer and Innovent strike a deal worth up to $10.5B for 12 cancer programs — the sixth mega-licensing deal out of China since last July. BMS wins Phase 3 for Pomalyst successor mezigdomide at ASCO 2026. Merck, Agios, MannKind, and PDUFA reauthorization round out a packed Friday.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Innovent Biologics, Bristol Myers Squibb, mezigdomide, Pomalyst, CELMoD, ASCO 2026, Merck, China licensing, Biosecure Act, oncology, Agios, tebapivat, MDS, MannKind, Afrezza, AstraZeneca, Imfinzi, Tremfya, Venclyxto, Dizal Pharma, EGFR, Replimune, melanoma, Allogene, PDUFA reauthorization, drug pricing, most-favored-nation, Roche, J&J, AbbVie, BMS 

Pfizer and Innovent strike a deal worth up to $10.5B for 12 cancer programs — the sixth mega-licensing deal out of China since last July. BMS wins Phase 3 for Pomalyst successor mezigdomide at ASCO 2026. Merck, Agios, MannKind, and PDUFA reauthorization round out a packed Friday.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Innovent Biologics, Bristol Myers Squibb, mezigdomide, Pomalyst, CELMoD, ASCO 2026, Merck, China licensing, Biosecure Act, oncology, Agios, tebapivat, MDS, MannKind, Afrezza, AstraZeneca, Imfinzi, Tremfya, Venclyxto, Dizal Pharma, EGFR, Replimune, melanoma, Allogene, PDUFA reauthorization, drug pricing, most-favored-nation, Roche, J&J, AbbVie, BMS

NOW PLAYING

May 29, 2026 | Pfizer's $10.5B Innovent Deal Extends China Licensing Wave; BMS Mezigdomide Phase 3

0:00 8:54

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 8 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on May 30, 2026.

What is this episode about?

Pfizer and Innovent strike a deal worth up to $10.5B for 12 cancer programs — the sixth mega-licensing deal out of China since last July. BMS wins Phase 3 for Pomalyst successor mezigdomide at ASCO 2026. Merck, Agios, MannKind, and PDUFA...

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!